Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Protagonist Therapeutics Inc’s stock clocked out at $77.5, up 2.34% from its previous closing price of $75.73. In other words, the price has increased by $2.34 from its previous closing price. On the day, 1.21 million shares were traded. PTGX stock price reached its highest trading level at $77.58 during the session, while it also had its lowest trading level at $75.17.
Ratios:
To gain a deeper understanding of PTGX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.45 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 129.96. For the most recent quarter (mrq), Quick Ratio is recorded 16.97 and its Current Ratio is at 16.97. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Barclays on September 17, 2025, initiated with a Overweight rating and assigned the stock a target price of $72.
On September 12, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $73.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $72.Citigroup initiated its Buy rating on June 17, 2025, with a $72 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 10 ’25 when Waddill William D. sold 12,000 shares for $81.62 per share. The transaction valued at 979,480 led to the insider holds 5,130 shares of the business.
WILLIAM WADDILL bought 12,000 shares of PTGX for $804,480 on Oct 10 ’25. On Sep 22 ’25, another insider, Waddill William D., who serves as the Director of the company, sold 4,000 shares for $64.25 each. As a result, the insider received 257,000 and left with 5,130 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 4821377536 and an Enterprise Value of 4262191104. As of this moment, Protagonist’s Price-to-Earnings (P/E) ratio for their current fiscal year is 108.76, and their Forward P/E ratio for the next fiscal year is 1878.33. For the stock, the TTM Price-to-Sale (P/S) ratio is 23.05 while its Price-to-Book (P/B) ratio in mrq is 7.21. Its current Enterprise Value per Revenue stands at 20.376 whereas that against EBITDA is 171.393.
Stock Price History:
The Beta on a monthly basis for PTGX is 2.18, which has changed by 0.6862489 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, PTGX has reached a high of $93.25, while it has fallen to a 52-week low of $33.31. The 50-Day Moving Average of the stock is 24.23%, while the 200-Day Moving Average is calculated to be 53.53%.
Shares Statistics:
It appears that PTGX traded 1.07M shares on average per day over the past three months and 2255170 shares per day over the past ten days. A total of 62.11M shares are outstanding, with a floating share count of 58.74M. Insiders hold about 5.58% of the company’s shares, while institutions hold 110.89% stake in the company. Shares short for PTGX as of 1759190400 were 6641782 with a Short Ratio of 6.21, compared to 1756425600 on 6846871. Therefore, it implies a Short% of Shares Outstanding of 6641782 and a Short% of Float of 12.8.
